Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Two trials were recently closed to accrual after reaching their accrual targets:

Canadian Cancer Trials Group IND.215 - A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens - was closed to accrual on October 16, 2015.

Canadian Cancer Trials Group MAC.15/SWOG1007 - A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer - was closed to accrual October 15, 2015. In Canada, 734 patients were registered to this trial and 327 patients were randomized.

Thank you to all participating centres, staff and patients for contributing to these trials.